Skip to main content

Systemic Corticosteroids

  • Chapter
  • First Online:
  • 803 Accesses

Abstract

Corticosteroids play an essential role in the treatment of many inflammatory autoimmune diseases and often are the first line treatment option for rapid clinical response. The significant therapeutic effects, however, are often accompanied by adverse side effects. The most common and serious complication is glucocorticoid-induced osteoporosis, remaining a potentially preventable but often poorly treated side effect. Although a rarer complication, osteonecrosis is more debilitating and occurs most commonly in patients taking higher doses of corticosteroids. Metabolic and endocrine side effects, including hyperglycemia and diabetes mellitus, are potential complications, even at low dosing. Hypothalamic-pituitary adrenal suppression with secondary adrenal insufficiency can be observed more rapidly at higher dosing or longer treatment duration, although has been observed with shorter duration and lower dosing of corticosteroids as well. Corticosteroid treatment may also induce or exacerbate psychiatric disorders such as anxiety, depression, and, less commonly, psychosis. Cardiovascular side effects may also occur with corticosteroid use including hypertension, dyslipidemia and atherosclerosis. Perhaps most notably and well-described is the increased susceptibility to infections accompanying corticosteroid use, thought to occur largely through several alterations in host defenses. Ophthalmologic side effects including cataract development and increased intraocular pressure require close monitoring in the setting of long-term glucocorticoid use. In addition, several adverse GI side effects including reflux disease, gastritis and peptic ulcers have been noted with corticosteroid use. Strategies for prevention of these adverse events remain an important component during corticosteroid management.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55:420–6.

    Article  PubMed  Google Scholar 

  2. Barnes P. How corticosteroids control inflammation: Quintiles Prize Lecture. Br J Pharmacol. 2006;148:245–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Rhen T, Cidlowski J. Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. N Engl J Med. 2005;353:1711–23.

    Article  CAS  PubMed  Google Scholar 

  4. Schacke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol. 2007;275:109.

    Article  PubMed  Google Scholar 

  5. Maricic M. Update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 2011;37:415–31.

    Article  PubMed  Google Scholar 

  6. Saag KG. Bone safety of low-dose glucocorticoids in rheumatic diseases. Ann N Y Acad Sci. 2014;1318:55–64.

    Article  CAS  PubMed  Google Scholar 

  7. Saag KG, Gehlbach SH, Curtis JR, et al. Trends in prevention of glucocorticoid-induced osteoporosis. J Rheumatol. 2006;33:1651–7.

    PubMed  Google Scholar 

  8. Natsui K, Tanaka K, Suda M, et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int. 2006;17:105–8.

    Article  CAS  PubMed  Google Scholar 

  9. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73–81.

    Article  CAS  PubMed  Google Scholar 

  10. Grossman J, Gordon R, Ranganath V, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62(11):1515–26.

    Article  Google Scholar 

  11. Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012;41:183–90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med. 2011;78:748–56.

    Article  PubMed  Google Scholar 

  13. Warrington TP, Bostick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81:1361–7.

    Article  CAS  PubMed  Google Scholar 

  14. Kenna HA, Poon AW, et al. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci. 2011;65:549–60.

    Article  CAS  PubMed  Google Scholar 

  15. Petri M, Perez-Gutthann S, Spence D, et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93:513–9.

    Article  CAS  PubMed  Google Scholar 

  16. El-Shaboury AH, Hayes TM. Hyperlipidemia in asthmatic patients receiving long-term steroid therapy. Br Med J. 1973;2:85–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Becker DM, Chamberlain B, Swank R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med. 1988;85:632–8.

    Article  CAS  PubMed  Google Scholar 

  18. Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int. 1987;31:1213–24.

    Article  CAS  PubMed  Google Scholar 

  19. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumaonia: associations with prednisone, disease-modifying antirheumatic drugs, and antitumor necrosis factor therapy. Arthritis Rheum. 2006;54:628–34.

    Article  CAS  PubMed  Google Scholar 

  20. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Antitumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:1754–64.

    Article  CAS  PubMed  Google Scholar 

  21. Jick SS, Lieberman ES, Rahman EU, Choi HK, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55:19–26.

    Article  PubMed  Google Scholar 

  22. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5–13.

    Article  CAS  PubMed  Google Scholar 

  23. Townsend HB, Saag KG. Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks. Clin Exp Rheumatol. 2004;22 Suppl 35:S77–82.

    CAS  PubMed  Google Scholar 

  24. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337:8–14.

    Article  CAS  PubMed  Google Scholar 

  25. Skalka HW, Prchal JT. Effect of corticosteroids on cataract formation. Arch Ophthalmol. 1980;98:1773–7.

    Article  CAS  PubMed  Google Scholar 

  26. Garbe E, LeLorier J, Biobin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet. 1997;350:979–82.

    Article  CAS  PubMed  Google Scholar 

  27. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735–40.

    Article  CAS  PubMed  Google Scholar 

  28. Garcia-Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001;3:98–101.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Henry B. Townsend MD .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Townsend, H.B., Turkiewicz, A.M., Whittier, X.A. (2016). Systemic Corticosteroids. In: Sami, N. (eds) Autoimmune Bullous Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-26728-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26728-9_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26726-5

  • Online ISBN: 978-3-319-26728-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics